Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study.
Adolescent
Adult
Aged
Antibodies, Viral
/ blood
COVID-19
/ blood
COVID-19 Serological Testing
/ methods
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G
/ blood
Longitudinal Studies
Luminescent Measurements
Male
Middle Aged
Pandemics
Russia
/ epidemiology
SARS-CoV-2
/ immunology
Self Report
Seroconversion
Seroepidemiologic Studies
Smoking
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 06 2021
21 06 2021
Historique:
received:
04
11
2020
accepted:
04
06
2021
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
8
7
2021
Statut:
epublish
Résumé
Properly conducted serological survey can help determine infection disease true spread. This study aims to estimate the seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia accounting for non-response bias. A sample of adults was recruited with random digit dialling, interviewed and invited for anti-SARS-CoV-2 antibodies. The seroprevalence was corrected with the aid of the bivariate probit model that jointly estimated individual propensity to agree to participate in the survey and seropositivity. 66,250 individuals were contacted, 6,440 adults agreed to be interviewed and blood samples were obtained from 1,038 participants between May 27 and June 26, 2020. Naïve seroprevalence corrected for test characteristics was 9.0% (7.2-10.8) by CMIA and 10.5% (8.6-12.4) by ELISA. Correction for non-response decreased estimates to 7.4% (5.7-9.2) and 9.1% (7.2-10.9) for CMIA and ELISA, respectively. The most pronounced decrease in bias-corrected seroprevalence was attributed to the history of any illnesses in the past 3 months and COVID-19 testing. Seroconversion was negatively associated with smoking status, self-reported history of allergies and changes in hand-washing habits. These results suggest that even low estimates of seroprevalence can be an overestimation. Serosurvey design should attempt to identify characteristics that are associated both with participation and seropositivity.
Identifiants
pubmed: 34155259
doi: 10.1038/s41598-021-92206-y
pii: 10.1038/s41598-021-92206-y
pmc: PMC8217236
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12930Références
Clin Chem. 2020 Nov 1;66(11):1405-1413
pubmed: 32777031
Nat Med. 2020 Sep;26(9):1494
pubmed: 32812013
Eur J Epidemiol. 2003;18(10):929-31
pubmed: 14598921
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Epidemiol Infect. 2010 Nov;138(11):1674-8
pubmed: 20196903
Clin Microbiol Infect. 2020 Sep;26(9):1256.e9-1256.e11
pubmed: 32531475
Eur J Epidemiol. 2020 Apr;35(4):331-333
pubmed: 32318914
Sci Rep. 2019 Dec 18;9(1):19360
pubmed: 31852944
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Virol Sin. 2020 Dec;35(6):752-757
pubmed: 32705575
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100747
pubmed: 33898863
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
Eur J Epidemiol. 2016 Jun;31(6):613-23
pubmed: 26975379
Am J Epidemiol. 2017 Jun 1;185(11):1048-1050
pubmed: 28535177
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Int J Epidemiol. 2013 Aug;42(4):1014-5
pubmed: 24062288
PLoS One. 2014 Nov 17;9(11):e112563
pubmed: 25402333
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
J Med Virol. 2020 Oct;92(10):1915-1921
pubmed: 32293753
Nat Med. 2020 Aug;26(8):1196-1199
pubmed: 32641783
Nat Med. 2020 Aug;26(8):1171-1172
pubmed: 32719488
J Clin Epidemiol. 1997 Oct;50(10):1123-8
pubmed: 9368520
Ann Epidemiol. 2003 Feb;13(2):105-10
pubmed: 12559669
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
BMC Med Res Methodol. 2020 Mar 14;20(1):65
pubmed: 32171240